XBIT - XBiotech: Well Funded Working On The Next Bermekimab And Undervalued
Investment Thesis
XBiotech Inc. 5-year share price performance. Source: TradingView.
XBiotech (XBIT) represents an interesting investment opportunity taking into account its past performance, current progress and niche field of drug development.
The company develops proprietary True Human™ monoclonal antibodies - identifying and cloning them from individuals who have exhibited resistance to certain types of disease - theoretically creating a safer, more effective and quicker-to-develop alternative to non-naturally occurring antibodies.
XBiotech targets areas of high unmet need and its most notable achievement to date has been the development of anti-inflammatory therapies that use